Professor Vincent Cottin (National Reference Centre for Rare Pulmonary Diseases, Lyon, France) spoke with touchRESPIRATORY around the Phase 2 PINTA study, investigating GLPG1205 for idiopathic pulmonary fibrosis.
The abstract ‘Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA).’ (Presentation ID 2904) was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- What is the mechanism of action of GLPG1205 and what was the rationale for its use in idiopathic pulmonary fibrosis? (0:22)
- Could you tell us a little about the Phase 2 PINTA study and the clinical endpoints investigated? (1:09)
- What were the efficacy and safety findings from the study? (2:35)
Disclosures: Vincent Cottin has disclosures with Boehringer Ingelheim and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
